Sensei Biotherapeutics (NASDAQ:FTH) Shares Up 5.3% – Time to Buy?

Shares of Sensei Biotherapeutics, Inc. (NASDAQ:FTH) were up 5.3% during trading on Monday . The company traded as high as $33.39 and last traded at $33.6850. Approximately 57,815 shares changed hands during trading, a decline of 72% from the average session volume of 209,544 shares. The stock had previously closed at $32.00.

Analysts Set New Price Targets

Several brokerages have recently weighed in on FTH. Citizens Jmp started coverage on shares of Sensei Biotherapeutics in a research report on Monday, July 20th. They issued an “outperform” rating and a $51.00 price objective on the stock. BTIG Research reaffirmed a “buy” rating and set a $55.00 target price on shares of Sensei Biotherapeutics in a report on Thursday, July 16th. Needham & Company LLC began coverage on Sensei Biotherapeutics in a research report on Friday, August 21st. They issued a “buy” rating and a $56.00 target price on the stock. Loop Capital set a $50.00 price target on shares of Sensei Biotherapeutics in a research report on Thursday, May 28th. Finally, Oppenheimer started coverage on Sensei Biotherapeutics in a report on Tuesday, July 28th. They issued an “outperform” rating and a $60.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Sensei Biotherapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $55.00.

Sensei Biotherapeutics Price Performance

The business’s 50-day moving average is $27.57. The stock has a market cap of $892.00 million, a price-to-earnings ratio of -0.24 and a beta of -0.25.

Sensei Biotherapeutics (NASDAQ:FTH) last issued its earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share for the quarter, beating analysts’ consensus estimates of ($5.04) by $2.20. On average, equities research analysts anticipate that Sensei Biotherapeutics, Inc. will post -13.18 EPS for the current year.

Insider Activity

In related news, major shareholder James Peyer sold 25,000 shares of Sensei Biotherapeutics stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $20.02, for a total transaction of $500,500.00. Following the sale, the insider directly owned 130,142 shares of the company’s stock, valued at approximately $2,605,442.84. The trade was a 16.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Brian C. Stephenson acquired 5,000 shares of the stock in a transaction that occurred on Wednesday, July 1st. The shares were bought at an average price of $23.50 per share, with a total value of $117,500.00. Following the completion of the transaction, the chief financial officer owned 46,688 shares in the company, valued at $1,097,168. This represents a 11.99% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have purchased 49,494 shares of company stock worth $1,188,822. Corporate insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of FTH. Vivo Capital LLC bought a new position in shares of Sensei Biotherapeutics in the 1st quarter valued at $22,758,000. Alyeska Investment Group L.P. bought a new stake in Sensei Biotherapeutics during the 2nd quarter worth $3,610,000. Stempoint Capital LP bought a new stake in Sensei Biotherapeutics during the 1st quarter worth $4,188,000. Bank of America Corp DE increased its holdings in Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after purchasing an additional 32,719 shares in the last quarter. Finally, Renaissance Technologies LLC increased its holdings in Sensei Biotherapeutics by 178.2% in the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock worth $1,010,000 after purchasing an additional 20,525 shares in the last quarter. 10.50% of the stock is currently owned by institutional investors and hedge funds.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.